Zomedica (ZOM) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 12, 2019
Document Information [Line Items]
Entity Registrant Name	Zomedica Pharmaceuticals Corp.
Entity Central Index Key	0001684144
Trading Symbol	zom
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		108,038,398
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Unaudited Interim Con

Condensed Unaudited Interim Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,487,651	$ 1,940,265
Prepaid expenses and deposits	1,497,425	1,867,034
Trade and other receivable	75,992	53,659
	4,061,068	3,860,958
Prepaid expenses and deposits		1,442,415
Property and equipment	805,218	717,088
Right-of-use asset	1,231,003
Intangible assets	513,735	13,058
	6,611,024	6,033,519
Current liabilities:
Accounts payable and accrued liabilities	1,577,525	2,376,519
	1,577,525	2,376,519
Shareholders' equity:
Series 1 preferred shares, without par value; 20 shares authorized (2018 - nil) Issued and outstanding 12 series 1 preferred shares (2018 - nil)	11,961,397
Unlimited common shares without par value; Issued and outstanding 108,038,398 common shares (2018 - 97,598,898)	38,647,822	30,410,648
Common stock subscribed		4,280,000
Additional paid-in capital	3,625,083	1,240,139
Accumulated deficit	(49,200,803)	(32,273,787)
	5,033,499	3,657,000
	$ 6,611,024	$ 6,033,519

Condensed Unaudited Interim C_2

Condensed Unaudited Interim Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	20	20
Preferred stock, shares issued (in shares)	12
Preferred stock, shares outstanding (in shares)	12
Capital stock, unlimited common shares	Unlimited	Unlimited
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, shares issued (in shares)	108,038,398	97,598,898
Capital stock, shares outstanding (in shares)	108,038,398	97,598,898

Condensed Unaudited Interim C_3

Condensed Unaudited Interim Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Expenses:
Research and development	$ 962,463	$ 630,371	$ 9,555,345	$ 3,765,332
General and administrative	1,404,952	834,570	5,557,661	3,243,232
Professional fees	279,237	293,484	1,230,151	1,001,886
Amortization - right-of-use asset	127,345		382,035
Amortization - intangible asset	273	431	810	1,810
Depreciation	70,096	86,162	201,075	150,320
Loss from operations	2,844,366	1,845,018	16,927,077	8,162,580
Loss on fixed assets		69,382	1,308	69,382
Interest expense			18,338
Gain on settlement of liabilities			(19,737)
Foreign exchange gain	1,313	(4,122)	30	(5,957)
Loss before income taxes	2,845,679	1,910,278	16,927,016	8,226,005
Income tax expense
Net loss and comprehensive loss	$ 2,845,679	$ 1,910,278	$ 16,927,016	$ 8,226,005
Weighted average number of common shares - basic and diluted (in shares)	108,038,398	94,514,905	105,711,459	92,534,667
Loss per share - basic and diluted (in dollars per share)	$ (0.03)	$ (0.02)	$ (0.16)	$ (0.09)

Condensed Unaudited Interim C_4

Condensed Unaudited Interim Consolidated Statements of Shareholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]		Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017		90,225,869
Balance at Dec. 31, 2017		$ 18,244,659			$ 1,768,526	$ (15,626,100)	$ 4,387,085
Stock issuance for services (in shares)		641,717
Stock issuance for services		$ 1,238,513					1,238,513
Stock issued from financing, number (in shares)		1,861,627
Stock issuance for financing, net of costs		$ 3,966,362					3,966,362
Stock-based compensation					7,288		$ 7,288
Stock issuance due to exercise of options (in shares)		1,866,996					1,866,996
Stock issuance due to exercise of options		$ 1,923,922			(386,898)		$ 1,537,024
Net loss						(8,226,005)	(8,226,005)
Balance (in shares) at Sep. 30, 2018		94,596,209
Balance at Sep. 30, 2018		$ 25,373,456			1,388,916	(23,852,105)	2,910,267
Balance (in shares) at Dec. 31, 2018		97,598,898
Balance at Dec. 31, 2018		$ 30,410,648		4,280,000	1,240,139	(32,273,787)	3,657,000
Stock issuance for services (in shares)		707,236	[1],[2]
Stock issuance for services		$ 792,104	[1],[2]				792,104
Stock issued from financing, number (in shares)	12	9,337,529
Stock issuance for financing, net of costs	$ 11,961,397	$ 6,690,922	[3],[4]	(4,280,000)			14,372,319
Stock-based compensation					2,539,092		$ 2,539,092
Stock issuance due to exercise of options (in shares)		394,735					394,735
Stock issuance due to exercise of options		$ 754,148			(154,148)		$ 600,000
Net loss						(16,927,016)	(16,927,016)
Balance (in shares) at Sep. 30, 2019	12	108,038,398
Balance at Sep. 30, 2019	$ 11,961,397	$ 38,647,822			$ 3,625,083	$ (49,200,803)	$ 5,033,499
[1]	On January 14, 2019, the Company issued 657,894 common shares in satisfaction of $1,000,000 of all remaining milestones under a License and Supply Agreement with a third party. The Company recognized $736,841 as research and development expense, based on the value of the common stock on the date of issuance;
[2]	On January 14, 2019, the Company settled $75,000 of amounts due to a vendor by issuing 49,342 common shares valued at $55,263 at the date of issuance. The Company recorded a $19,737 gain on the settlement of liabilities during the three months ended March 31, 2019;
[3]	On January 14, 2019, the Company completed a non-brokered private placement, and issued 2,815,789 common shares. Gross proceeds of $4,280,000 were received prior to December 31, 2018. The Company recorded $465 of share issuance costs as an offset to common stock;
[4]	On March 28, 2019, the Company completed an underwritten public offering of its common stock pursuant to which the Company sold an aggregate 6,521,740 common shares for gross proceeds of $3,000,000. The Company recorded nil and $588,613 of share issuance costs as an offset to common stock in the three and nine months ended September 30, 2019.

Condensed Unaudited Interim C_5

Condensed Unaudited Interim Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Cash flows used in operating activities:
Net loss for the period	$ (2,845,679)	$ (1,910,278)	$ (16,927,016)	$ (8,226,005)
Adjustments for
Depreciation	(70,096)	(86,162)	(201,075)	(150,320)
Amortization - intangible asset	273	431	810	1,810
Amortization - right-of-use asset	127,345		382,035
Loss on fixed assets		69,382	1,308	69,382
Stock issued for services			792,104	1,238,513
Stock-based compensation	197,988		2,539,092	7,288
Change in non-cash operating working capital
Trade and other receivable	19,558	11,885	(22,333)	(9,470)
Prepaid expenses	(122,315)	56,399	140,695	(191,365)
Deposits	21,366	(1,281,617)	(76,709)	(1,311,463)
Accounts payable and accrued liabilities	(1,378,710)	(403,423)	(798,994)	451,643
	(3,910,078)	(3,371,059)	(13,767,933)	(7,819,347)
Cash flows (used) from financing activities:
Cash proceeds from financing of preferred shares			12,000,000
Cash proceeds from financing of common shares			3,000,000	4,002,496
Cash received from stock option exercises	0	98,716	600,000	1,537,024
Cash paid on stock issuance costs	(1,414)	(12,328)	(627,681)	(36,135)
	(1,414)	86,388	14,972,319	5,503,385
Cash flows used in investing activities:
Investment in intangibles	(501,487)		(501,487)
Investment in property and equipment	(80,950)	(467,675)	(155,513)	(605,368)
	(582,437)	(467,675)	(657,000)	(605,368)
Increase (decrease) in cash and cash equivalents	(4,493,929)	(3,752,346)	547,386	(2,921,330)
Cash and cash equivalents, beginning of period	6,981,580	4,279,163	1,940,265	3,448,147
Cash and cash equivalents, end of period	2,487,651	526,817	2,487,651	526,817
Supplemental cash flow information:
Interest paid	$ 12,164		$ 18,338

Note 1 - Nature of Operations a

Note 1 - Nature of Operations and Going Concern	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	1. Nature of operations and going concern Zomedica Pharmaceuticals Corp. ("Zomedica" or the “Company”) was incorporated on January 7, 2013 Business Corporations Act 2.4 May 14, 2015 Canada Business Corporations Act On April 21, 2016, three 9674128 one 2.5 2.4 Capital Pool Companies May 2, 2016. June 21, 2016, Zomedica has one 100 190, 48108 1250, 639 5th T2P 0M9. On November 20, 2017, 1 November 21, 2017, Going concern The consolidated financial statements are prepared on a going concern basis, which assumes that the Company will be able to meet its obligations and continue its operations for the next twelve $49,200,803 September 30, 2019 ( December 31, 2018 - $32,273,787 no In order for the Company to continue as a going concern and fund any significant expansion of its operations or R&D activities, the Company will require significant additional capital. The Company’s ultimate success will depend on whether its future product candidates receive the necessary regulatory approval and it is able to successfully market approved products. The Company cannot be certain that it will be able to receive regulatory approval for any of its future product candidates, or that it will reach the level of sales and revenues necessary to achieve and sustain profitability. The availability of equity or debt financing will be affected by, among other things, the results of the Company’s research and development, its ability to obtain regulatory approvals, the market acceptance of its products, the state of the capital markets generally, strategic alliance agreements, and other relevant commercial considerations. In addition, if the Company raises additional funds by issuing equity securities, its then existing security holders will likely experience dilution, and the incurring of indebtedness would result in increased debt service obligations and could require the Company to agree to operating and financial covenants that would restrict its operations. Any failure on its part to raise additional funds on terms favorable to the Company or at all, may not

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of preparation The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements. Basis of consolidation These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc. All inter-company accounts and transactions have been eliminated on consolidation.

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant accounting policies Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; deferred income taxes and forecasting future cash flows for assessing the going concern assumption. Basis of measurement The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted. Functional and reporting currencies The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency. The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements. Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. Translation of foreign currencies In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss. Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not three nine September 30, 2019 Comprehensive loss The Company follows ASC topic 220. no Recently adopted accounting pronouncements In February 2016, No. 2016 02, 842 12 842 December 15, 2018. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. The Company adopted the new standard with an initial application date of January 1, 2019 not not January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permits the Company not not not On August 29, 2018, 2018 15, 350 40 2018 15 350 350 40 December 15, 2019. The Company has chosen to adopt this guidance during the three September 30, 2019.

Note 4 - Critical Accounting Ju

Note 4 - Critical Accounting Judgments and Key Sources of Estimation Uncertainty	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Critical Accounting Judgments and Key Sources of Estimation Uncertainly [Text Block]	4. Critical accounting judgments and key sources of estimation uncertainty The preparation of consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not may The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Critical areas of estimation and judgements in applying accounting policies include the following: Going concern These condensed unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP on a going concern basis, which assumes the realization of assets and discharge of liabilities in the normal course of business within the foreseeable future. Management uses judgment in determining assumptions for cash flow projections, such as anticipated financing, anticipated sales and future commitments to assess the Company’s ability to continue as a going concern. A critical judgment is that the Company continues to raise funds going forward and satisfy their obligations as they become due. Stock-based payments The Company estimates the fair value of convertible securities such as options using the Black-Scholes option-pricing model which requires significant estimation around assumptions and inputs such as expected term to maturity, expected volatility and expected dividends. Useful lives of property and equipment The Company reviews the estimated useful lives of property and equipment with definite useful lives at the end of each year and assesses whether the useful lives of certain items should be shortened or extended, due to various factors including technology, competition and revised service offerings. During the three nine September 30, 2019, not may not Deferred income taxes The calculation of deferred income taxes is based on assumptions which are subject to uncertainty as to timing and which tax rates are expected to apply when temporary differences reverse. Deferred tax recorded is also subject to uncertainty regarding the magnitude of non-capital losses available for carry forward and of the balances in various tax pools. By their nature, these estimates are subject to measurement uncertainty, and the effect on the financial statements from changes in such estimates in future period could be material. Deferred tax assets are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred tax assets are reviewed at each balance sheet date and adjusted to the extent that it is no

Note 5 - Prepaid Expenses and D

Note 5 - Prepaid Expenses and Deposits	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Prepaid Rent [Text Block]	5. Prepaid expenses and deposits September 30, December 31, 2019 2018 Prepaid rent (i) $ - $ 1,613,038 Deposits (ii) 1,202,814 1,596,104 Prepaid FDA fees 31,497 - Prepaid marketing (iii) 36,596 37,465 Prepaid insurance (iii) 156,044 33,372 Other (iv) 70,474 29,470 Total $ 1,497,425 $ 3,309,449 (i) On July 31, 2018, 18,640 $1,269,073. January 1, 2019, $1,613,038. 842, December 31, 2018, $509,380 (ii) Deposits include payments made to vendors in advance and are primarily associated with research activity, deposits for leasehold improvements, and equipment purchases. As of September 30, 2019, December 31, 2018, $1,202,814 $922,347 (iii) As of September 30, 2019, December 31, 2018, (iv) Other prepaid expenses and deposits are comprised of subscription payments and software licensing. As of September 30, 2019, December 31, 2018,

Note 6 - Property and Equipment

Note 6 - Property and Equipment	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and equipment Computer equipment Furniture and equipment Laboratory equipment Leasehold improvements Total Cost Balance at December 31, 2017 $ 151,155 $ 76,058 $ 245,729 $ 36,957 $ 509,899 Additions 18,847 105,821 246,375 256,954 627,997 Disposals - - (139,467 ) (10,936 ) (150,403 ) Balance at December 31, 2018 170,002 181,879 352,637 282,975 987,493 Additions 218,076 3,414 3,350 65,673 290,513 Disposals (2,210 ) - - - (2,210 ) Balance at September 30, 2019 385,868 185,293 355,987 348,648 1,275,796 Accumulated depreciation Balance at December 31, 2017 42,802 11,845 74,875 9,220 138,742 Depreciation 62,116 17,740 86,368 37,460 203,684 Disposals - - (61,547 ) (10,474 ) (72,021 ) Balance at December 31, 2018 104,918 29,585 99,696 36,206 270,405 Depreciation 60,561 19,885 51,151 69,478 201,075 Disposals (902 ) - - - (902 ) Balance at September 30, 2019 164,577 49,470 150,847 105,684 470,578 Net book value as at: December 31, 2018 $ 65,084 $ 152,294 $ 252,941 $ 246,769 $ 717,088 September 30, 2019 $ 221,291 $ 135,823 $ 205,140 $ 242,964 $ 805,218 In February 2019, $135,000

Note 7 - Intangible Assets

Note 7 - Intangible Assets	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7. Intangible assets Computer software Trademarks Total intangible assets Cost Balance at December 31, 2017 $ 5,143 $ 16,236 $ 21,379 Additions - - - Balance at December 31, 2018 5,143 16,236 21,379 Additions 501,487 - 501,487 Balance at September 30, 2019 506,630 16,236 522,866 Accumulated amortization Balance at December 31, 2017 4,143 2,095 6,238 Amortization 1,000 1,083 2,083 Balance at December 31, 2018 5,143 3,178 8,321 Amortization - 810 810 Balance at September 30, 2019 5,143 3,988 9,131 Net book value as at: December 31, 2018 $ - $ 13,058 $ 13,058 September 30, 2019 $ 501,487 $ 12,248 $ 513,735

Note 8 - Leases

Note 8 - Leases	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases As discussed in Note 3, 842 January 1, 2019. two $1,613,038 The Company amortizes the asset on a straight-line basis and records the expense in the consolidated statement of operations and comprehensive loss. During the three nine September 30, 2019, $127,345 $382,035 2018 nil

Note 9 - Loan Arrangements

Note 9 - Loan Arrangements	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	9. Loan arrangements On October 17, 2017, may $5,000,000, five 5 may one $250,000 one not two may fourteen 14% September 30, 2019, no

Note 10 - Preferred Stock

Note 10 - Preferred Stock	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred stock The Company is authorized to issue up to 20 1 $1,000,000. 1 not not 1 not 9 9 1 1 9 1 Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series 1 1 1 In the event of a fundamental transaction (defined to include an amalgamation, merger or other business combination transaction involving our company in which our shareholders do not 50% may third 1 1 1 5.0 9.0 1 Issued and outstanding preferred stock: Number of preferred Preferred stock stock amount Balance at December 31, 2018 - $ - Stock issued from financing (i) 12 11,961,397 Balance at September 30, 2019 12 $ 11,961,397 (i) On May 9, 2019, $12,000,000 1 $1,000,000 1 $5,000,000 May 9, 2019 $7,000,000 June 7, 2019. $1,414 $38,603 three nine September 30, 2019

Note 11 - Common Stock

Note 11 - Common Stock	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Common stock The Company is authorized to issue an unlimited number of common shares, all without par value. Issued and outstanding common stock: Number of common Common stock stock amount Balance at December 31, 2017 90,225,869 $ 18,244,659 Stock issuance for services 641,717 1,238,513 Stock issuance for financing, net of costs 1,861,627 3,966,362 Stock issuance due to exercise of options 1,866,996 1,923,922 Balance at September 30, 2018 94,596,209 $ 25,373,456 Balance at December 31, 2018 97,598,898 $ 30,410,648 Stock issuance for services (i and ii) 707,236 792,104 Stock issuance from financing (iii and iv) 9,337,529 6,690,922 Stock issuance due to exercise of options 394,735 754,148 Balance at September 30, 2019 108,038,398 $ 38,647,822 (i) On January 14, 2019, $75,000 49,342 $55,263 $19,737 three March 31, 2019; (ii) On January 14, 2019, 657,894 $1,000,000 third $736,841 (iii) On January 14, 2019, 2,815,789 $4,280,000 December 31, 2018.The $465 (iv) On March 28, 2019, 6,521,740 $3,000,000. nil $588,613 three nine September 30, 2019.

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock-based compensation During the three September 30, 2019, nil three September 30, 2018, 85,000 nine September 30, 2019, 394,735 nine September 30, 2018, 1,866,996 three September 30, 2019, 1,500,000 nine September 30, 2019, 7,495,000 one three nine September 30, 2018, nil The continuity of stock options are as follows: Number of options Weighted avg Balance at December 31, 2018 422,004 $ 1.95 Stock options granted January 10, 2019 5,995,000 1.52 Stock options expired February 24, 2019 (35,000 ) 1.12 Stock options exercised March 8, 2019 (164,473 ) 1.52 Stock options exercised March 15, 2019 (164,473 ) 1.52 Stock options exercised March 29, 2019 (65,789 ) 1.52 Stock options expired May 23, 2019 (10,000 ) 1.52 Stock options expired June 16, 2019 (40,000 ) 1.52 Stock options cancelled August 13, 2019 (5,000 ) 1.52 Stock options expired August 14, 2019 (392,004 ) 2.07 Stock options granted August 19, 2019 500,000 0.26 Stock options granted August 19, 2019 100,000 0.35 Stock options granted August 19, 2019 100,000 0.45 Stock options granted August 19, 2019 100,000 0.55 Stock options granted August 19, 2019 100,000 0.65 Stock options granted August 19, 2019 100,000 0.75 Stock options granted September 16, 2019 500,000 0.43 Balance at September 30, 2019 7,040,265 $ 1.28 (i) As of the year ended December 31, 2018, $2.65. As at September 30, 2019, Grant date Exercise price Number of Number of Weighted Avg January 10, 2019 $ 1.52 5,540,265 5,540,265 1.28 August 19, 2019 0.26 500,000 500,000 1.88 August 19, 2019 0.35 100,000 100,000 1.88 August 19, 2019 0.45 100,000 100,000 1.88 August 19, 2019 0.55 100,000 100,000 1.88 August 19, 2019 0.65 100,000 100,000 1.88 August 19, 2019 0.75 100,000 100,000 1.88 September 16, 2019 0.43 500,000 500,000 1.96 Balance at September 30, 2019 7,040,265 7,040,265 The fair value of options granted during the three nine September 30, 2019 January 10, 2019 August 19, 2019 September 16, 2019 Volatility 68% 87% 89% Risk-free interest rate 2.56% 1.48% 1.74% Expected life (years) 2 2 2 Dividend yield 0 0 0 Common share price $1.23 $0.26 $0.42 Strike price $1.52 $ 0.26 - $ 0.75 $0.43 Forfeiture rate nil nil nil The Company recorded $197,988 three September 30, 2019 ( three September 30, 2018 – nil $2,539,092 nine September 30, 2019 ( nine September 30, 2018 - $7,288 nil three September 30, 2019. $600,000 $154,148 nine September 30, 2019. $98,716 $34,608 three September 30, 2018. $1,537,024 $386,898 nine September 30, 2018. The Company has estimated its stock option forfeitures to be nil three nine September 30, 2019 ( three nine September 2018 - nil

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and contingencies On October 1, 2018, one September 1, 2019, one one not 842 one 2019 $ 12,480 2020 33,280 Total $ 45,760 On November 26, 2018, • 1 st September 12, 2019, ° $3,000,000 or ° $1,500,000 $1.95 • 2 nd February 19, 2020 - $2,000,000 As at September 30, 2019, On May 10, 2018, • 1 st $3,500,000 • 2 nd $3,500,000 10 As at September 30, 2019, From time to time, the Company may September 30, 2019, November 12, 2019, not On November 1, 2019, 1:19 01108 TM Under the terms of the Development and Supply Agreement, dated November 26, 2018, third

Note 14 - Financial Instruments

Note 14 - Financial Instruments	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	14. Financial instruments (a) Fair values The Company follows ASC topic 820, 820 820 three three three Level 1 Level 2 1 Level 3 The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments. (b) Interest rate and credit risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank and a U.S. Bank. The Company’s cash is not (c) Foreign exchange risk The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 10% $0.1 (d) Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at June 30, 2019 December 31, 2018: September 30, 2019 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,577,525 - - - - 1,577,525 1,577,525 - - - - 1,577,525 December 31, 2018 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 2,376,519 - - - - 2,376,519 2,376,519 - - - - 2,376,519

Note 15 - Segmented Information

Note 15 - Segmented Information	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. Segmented information The Company's operations comprise a single reportable segment engaged in the research, development targeting health and wellness solutions for the companion animal. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in the United States of America (“US”). September 30, December 31, 2019 2018 $ $ Total assets Canada 431,063 383,567 US 6,179,961 5,649,952 Total US property and equipment 805,218 717,088 Total US right-of-use asset 1,231,003 - 2,036,221 717,088

Note 16 - Schedule of Expenses

Note 16 - Schedule of Expenses	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Operating Expenses [Text Block]	16. Schedule of expenses For the three months ended September 30, For the three months ended September 30, 2019 2018 Research and Professional General and Research and Professional General and Development Fees Administrative Development Fees Administrative Salaries, bonus and benefits $ 129,319 $ - $ 849,458 $ 164,267 $ - $ 454,786 Contracted expenditures 661,917 - - 259,947 - - Marketing and investor relations - - 165,837 - - 53,996 Travel and accommodation 8,327 - 198,993 8,023 - 36,491 Insurance 19,497 - 66,029 20,855 - 76,903 License fees - - - - - - Office 11,565 - 80,032 6,665 - 82,416 Consultants 29,343 279,237 - 80,425 293,484 - Regulatory 31,773 - 26,163 19,247 - 32,904 Rent - - 7,603 15,396 - 90,463 Supplies 70,722 - 10,837 55,546 - 6,611 Total $ 962,463 $ 279,237 $ 1,404,952 $ 630,371 $ 293,484 $ 834,570 For the nine months ended September 30, For the nine months ended September 30, 2019 2018 Research and Professional General and Research and Professional General and Development Fees Administrative Development Fees Administrative Salaries, bonus and benefits $ 579,110 $ - $ 4,422,480 $ 490,706 $ - $ 1,957,341 Contracted expenditures 2,474,483 - - 968,159 - - Marketing and investor relations - - 297,252 - - 177,151 Travel and accommodation 21,103 - 318,730 13,360 - 228,359 Insurance 76,402 - 179,367 65,099 - 234,646 License fees 5,936,841 - - 1,738,513 - - Office 31,162 - 216,521 41,312 - 220,823 Consultants 178,223 1,230,151 - 169,613 1,001,886 - Regulatory 95,418 - 76,333 57,422 - 226,604 Rent - - 19,483 31,047 - 176,501 Supplies 162,603 - 27,495 190,101 - 21,807 Total $ 9,555,345 $ 1,230,151 $ 5,557,661 $ 3,765,332 $ 1,001,886 $ 3,243,232

Note 17 - Capital Risk Manageme

Note 17 - Capital Risk Management	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Capital Risk Management [Text Block]	17. Capital risk management The capital of the Company includes equity, which is comprised of issued common capital stock, additional paid-in capital, and accumulated deficit. The Company's objective when managing its capital is to safeguard the ability to continue as a going concern in order to provide returns for its shareholders, and other stakeholders and to maintain a strong capital base to support the Company's core activities.

Note 18 - Loss Per Share

Note 18 - Loss Per Share	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	18. Loss per share For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Numerator Net loss for the period $ 2,845,679 $ 1,910,278 $ 16,927,016 $ 8,226,005 Denominator Weighted average shares - basic 108,038,398 94,514,905 105,711,459 92,534,667 Stock options - - - - Denominator for diluted loss per share 108,038,398 94,514,905 105,711,459 92,534,667 Loss per share - basic and diluted $ (0.03 ) $ (0.02 ) $ (0.16 ) $ (0.09 ) For the above-mentioned periods, the Company had securities outstanding which could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti-dilutive.

Note 19 - Related Party Transac

Note 19 - Related Party Transactions and Key Management Compensation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	19. Related party transactions and key management compensation Key management personnel are comprised of the Company’s directors and executive officers. In addition to their salaries, key management personnel also receive share-based compensation. Key management personnel compensation is as follows: For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Salaries and benefits, including bonuses $ 251,737 $ 324,784 $ 887,635 $ 1,046,449 Stock-based compensation 100,002 - 1,744,327 - Total $ 351,739 $ 324,784 $ 2,631,962 $ 1,046,449

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; deferred income taxes and forecasting future cash flows for assessing the going concern assumption.
Basis of Measurement [Policy Text Block]	Basis of measurement The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.
Functional and Reporting Currencies [Policy Text Block]	Functional and reporting currencies The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency. The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements.
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730.
Share Issue Costs [Policy Text Block]	Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign currencies In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss.
Share-based Payment Arrangement [Policy Text Block]	Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not three nine September 30, 2019
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss The Company follows ASC topic 220. no
New Accounting Pronouncements, Policy [Policy Text Block]	Recently adopted accounting pronouncements In February 2016, No. 2016 02, 842 12 842 December 15, 2018. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. The Company adopted the new standard with an initial application date of January 1, 2019 not not January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the ‘package of practical expedients’, which permits the Company not not not On August 29, 2018, 2018 15, 350 40 2018 15 350 350 40 December 15, 2019. The Company has chosen to adopt this guidance during the three September 30, 2019.

Note 5 - Prepaid Expenses and_2

Note 5 - Prepaid Expenses and Deposits (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Prepaid Expenses and Deposits [Table Text Block]	September 30, December 31, 2019 2018 Prepaid rent (i) $ - $ 1,613,038 Deposits (ii) 1,202,814 1,596,104 Prepaid FDA fees 31,497 - Prepaid marketing (iii) 36,596 37,465 Prepaid insurance (iii) 156,044 33,372 Other (iv) 70,474 29,470 Total $ 1,497,425 $ 3,309,449

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	Computer equipment Furniture and equipment Laboratory equipment Leasehold improvements Total Cost Balance at December 31, 2017 $ 151,155 $ 76,058 $ 245,729 $ 36,957 $ 509,899 Additions 18,847 105,821 246,375 256,954 627,997 Disposals - - (139,467 ) (10,936 ) (150,403 ) Balance at December 31, 2018 170,002 181,879 352,637 282,975 987,493 Additions 218,076 3,414 3,350 65,673 290,513 Disposals (2,210 ) - - - (2,210 ) Balance at September 30, 2019 385,868 185,293 355,987 348,648 1,275,796 Accumulated depreciation Balance at December 31, 2017 42,802 11,845 74,875 9,220 138,742 Depreciation 62,116 17,740 86,368 37,460 203,684 Disposals - - (61,547 ) (10,474 ) (72,021 ) Balance at December 31, 2018 104,918 29,585 99,696 36,206 270,405 Depreciation 60,561 19,885 51,151 69,478 201,075 Disposals (902 ) - - - (902 ) Balance at September 30, 2019 164,577 49,470 150,847 105,684 470,578 Net book value as at: December 31, 2018 $ 65,084 $ 152,294 $ 252,941 $ 246,769 $ 717,088 September 30, 2019 $ 221,291 $ 135,823 $ 205,140 $ 242,964 $ 805,218

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Computer software Trademarks Total intangible assets Cost Balance at December 31, 2017 $ 5,143 $ 16,236 $ 21,379 Additions - - - Balance at December 31, 2018 5,143 16,236 21,379 Additions 501,487 - 501,487 Balance at September 30, 2019 506,630 16,236 522,866 Accumulated amortization Balance at December 31, 2017 4,143 2,095 6,238 Amortization 1,000 1,083 2,083 Balance at December 31, 2018 5,143 3,178 8,321 Amortization - 810 810 Balance at September 30, 2019 5,143 3,988 9,131 Net book value as at: December 31, 2018 $ - $ 13,058 $ 13,058 September 30, 2019 $ 501,487 $ 12,248 $ 513,735

Note 10 - Preferred Stock (Tabl

Note 10 - Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Preferred Stock [Table Text Block]	Number of preferred Preferred stock stock amount Balance at December 31, 2018 - $ - Stock issued from financing (i) 12 11,961,397 Balance at September 30, 2019 12 $ 11,961,397

Note 11 - Common Stock (Tables)

Note 11 - Common Stock (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Number of common Common stock stock amount Balance at December 31, 2017 90,225,869 $ 18,244,659 Stock issuance for services 641,717 1,238,513 Stock issuance for financing, net of costs 1,861,627 3,966,362 Stock issuance due to exercise of options 1,866,996 1,923,922 Balance at September 30, 2018 94,596,209 $ 25,373,456 Balance at December 31, 2018 97,598,898 $ 30,410,648 Stock issuance for services (i and ii) 707,236 792,104 Stock issuance from financing (iii and iv) 9,337,529 6,690,922 Stock issuance due to exercise of options 394,735 754,148 Balance at September 30, 2019 108,038,398 $ 38,647,822

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of options Weighted avg Balance at December 31, 2018 422,004 $ 1.95 Stock options granted January 10, 2019 5,995,000 1.52 Stock options expired February 24, 2019 (35,000 ) 1.12 Stock options exercised March 8, 2019 (164,473 ) 1.52 Stock options exercised March 15, 2019 (164,473 ) 1.52 Stock options exercised March 29, 2019 (65,789 ) 1.52 Stock options expired May 23, 2019 (10,000 ) 1.52 Stock options expired June 16, 2019 (40,000 ) 1.52 Stock options cancelled August 13, 2019 (5,000 ) 1.52 Stock options expired August 14, 2019 (392,004 ) 2.07 Stock options granted August 19, 2019 500,000 0.26 Stock options granted August 19, 2019 100,000 0.35 Stock options granted August 19, 2019 100,000 0.45 Stock options granted August 19, 2019 100,000 0.55 Stock options granted August 19, 2019 100,000 0.65 Stock options granted August 19, 2019 100,000 0.75 Stock options granted September 16, 2019 500,000 0.43 Balance at September 30, 2019 7,040,265 $ 1.28
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Grant date Exercise price Number of Number of Weighted Avg January 10, 2019 $ 1.52 5,540,265 5,540,265 1.28 August 19, 2019 0.26 500,000 500,000 1.88 August 19, 2019 0.35 100,000 100,000 1.88 August 19, 2019 0.45 100,000 100,000 1.88 August 19, 2019 0.55 100,000 100,000 1.88 August 19, 2019 0.65 100,000 100,000 1.88 August 19, 2019 0.75 100,000 100,000 1.88 September 16, 2019 0.43 500,000 500,000 1.96 Balance at September 30, 2019 7,040,265 7,040,265
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	January 10, 2019 August 19, 2019 September 16, 2019 Volatility 68% 87% 89% Risk-free interest rate 2.56% 1.48% 1.74% Expected life (years) 2 2 2 Dividend yield 0 0 0 Common share price $1.23 $0.26 $0.42 Strike price $1.52 $ 0.26 - $ 0.75 $0.43 Forfeiture rate nil nil nil

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2019 $ 12,480 2020 33,280 Total $ 45,760

Note 14 - Financial Instrumen_2

Note 14 - Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities [Table Text Block]	September 30, 2019 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,577,525 - - - - 1,577,525 1,577,525 - - - - 1,577,525 December 31, 2018 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 2,376,519 - - - - 2,376,519 2,376,519 - - - - 2,376,519

Note 15 - Segmented Informati_2

Note 15 - Segmented Information (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	September 30, December 31, 2019 2018 $ $ Total assets Canada 431,063 383,567 US 6,179,961 5,649,952 Total US property and equipment 805,218 717,088 Total US right-of-use asset 1,231,003 - 2,036,221 717,088

Note 16 - Schedule of Expenses

Note 16 - Schedule of Expenses (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Operating Expenses [Table Text Block]	For the three months ended September 30, For the three months ended September 30, 2019 2018 Research and Professional General and Research and Professional General and Development Fees Administrative Development Fees Administrative Salaries, bonus and benefits $ 129,319 $ - $ 849,458 $ 164,267 $ - $ 454,786 Contracted expenditures 661,917 - - 259,947 - - Marketing and investor relations - - 165,837 - - 53,996 Travel and accommodation 8,327 - 198,993 8,023 - 36,491 Insurance 19,497 - 66,029 20,855 - 76,903 License fees - - - - - - Office 11,565 - 80,032 6,665 - 82,416 Consultants 29,343 279,237 - 80,425 293,484 - Regulatory 31,773 - 26,163 19,247 - 32,904 Rent - - 7,603 15,396 - 90,463 Supplies 70,722 - 10,837 55,546 - 6,611 Total $ 962,463 $ 279,237 $ 1,404,952 $ 630,371 $ 293,484 $ 834,570 For the nine months ended September 30, For the nine months ended September 30, 2019 2018 Research and Professional General and Research and Professional General and Development Fees Administrative Development Fees Administrative Salaries, bonus and benefits $ 579,110 $ - $ 4,422,480 $ 490,706 $ - $ 1,957,341 Contracted expenditures 2,474,483 - - 968,159 - - Marketing and investor relations - - 297,252 - - 177,151 Travel and accommodation 21,103 - 318,730 13,360 - 228,359 Insurance 76,402 - 179,367 65,099 - 234,646 License fees 5,936,841 - - 1,738,513 - - Office 31,162 - 216,521 41,312 - 220,823 Consultants 178,223 1,230,151 - 169,613 1,001,886 - Regulatory 95,418 - 76,333 57,422 - 226,604 Rent - - 19,483 31,047 - 176,501 Supplies 162,603 - 27,495 190,101 - 21,807 Total $ 9,555,345 $ 1,230,151 $ 5,557,661 $ 3,765,332 $ 1,001,886 $ 3,243,232

Note 18 - Loss Per Share (Table

Note 18 - Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Numerator Net loss for the period $ 2,845,679 $ 1,910,278 $ 16,927,016 $ 8,226,005 Denominator Weighted average shares - basic 108,038,398 94,514,905 105,711,459 92,534,667 Stock options - - - - Denominator for diluted loss per share 108,038,398 94,514,905 105,711,459 92,534,667 Loss per share - basic and diluted $ (0.03 ) $ (0.02 ) $ (0.16 ) $ (0.09 )

Note 19 - Related Party Trans_2

Note 19 - Related Party Transactions and Key Management Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Key Management Personnel Compensation [Table Text Block]	For the three months ended September 30, For the nine months ended September 30, 2019 2018 2019 2018 Salaries and benefits, including bonuses $ 251,737 $ 324,784 $ 887,635 $ 1,046,449 Stock-based compensation 100,002 - 1,744,327 - Total $ 351,739 $ 324,784 $ 2,631,962 $ 1,046,449

Note 1 - Nature of Operations_2

Note 1 - Nature of Operations and Going Concern (Details Textual) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Retained Earnings (Accumulated Deficit), Ending Balance	$ (49,200,803)	$ (32,273,787)

Note 3 - Significant Accounti_2

Note 3 - Significant Accounting Policies (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Other Comprehensive Income (Loss), Net of Tax, Total	$ 0

Note 5 - Prepaid Expenses and_3

Note 5 - Prepaid Expenses and Deposits (Details Textual)	Jul. 31, 2018USD ($)ft²	Sep. 30, 2019USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Payments for Rent	$ 1,269,073
Operating Lease, Right-of-Use Asset		$ 1,231,003	$ 1,613,038
Prepaid Rent				509,380
Deposits Assets, Current		$ 1,202,814		$ 922,347
Wickfield Phoenix LLC Office Space [Member]
Area of Real Estate Property | ft²	18,640

Note 5 - Prepaid Expenses and_4

Note 5 - Prepaid Expenses and Deposits - Summary of Prepaid Expenses and Deposits (Details) - USD ($)		Sep. 30, 2019	Dec. 31, 2018
Prepaid rent	[1]		$ 1,613,038
Deposits	[2]	1,202,814	1,596,104
Prepaid FDA fees		31,497
Prepaid marketing	[3]	36,596	37,465
Prepaid insurance	[3]	156,044	33,372
Other	[4]	70,474	29,470
Total		$ 1,497,425	$ 3,309,449
[1]	On July 31, 2018, the Company entered into an amended lease agreement with Wickfield Phoenix LLC for an additional 18,640 square feet of office space. The Company prepaid the full outstanding balance of $1,269,073. As of January 1, 2019, the balance of the prepaid rent, inclusive of the original and amended lease amounts was $1,613,038. In accordance with ASC 842, this amount was reclassified as a right-of-use asset in the consolidated balance sheet. As of December 31, 2018, the Company classified $509,380 as a current asset in the consolidated balance sheet;
[2]	Deposits include payments made to vendors in advance and are primarily associated with research activity, deposits for leasehold improvements, and equipment purchases. As of September 30, 2019, and December 31, 2018, the Company classified $1,202,814 and $922,347 as a current asset in the consolidated balance sheet, respectively;
[3]	As of September 30, 2019, and December 31, 2018, all amounts were classified as a current asset in the consolidated balance sheet;
[4]	Other is comprised of subscription payments and software licensing. As of September 30, 2019, and December 31, 2018, the Company classified all amounts as a current asset in the consolidated balance sheet.

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual)	1 Months Ended
	Feb. 28, 2019USD ($)
Reclassificaiton From Prepaid Assets to Property, Plant and Equipment	$ 135,000

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Cost, Beginning Balance	$ 987,493	$ 509,899
Cost, Additions	290,513	627,997
Cost, Disposals	(2,210)	(150,403)
Cost, Ending Balance	1,275,796	987,493
Accumulated Depreciation, Beginning Balance	270,405	138,742
Accumulated Depreciation, Depreciation	201,075	203,684
Accumulated Depreciation, Disposals	(902)	(72,021)
Accumulated Depreciation, Ending Balance	470,578	270,405
Net Book Value	805,218	717,088
Computer Equipment [Member]
Cost, Beginning Balance	170,002	151,155
Cost, Additions	218,076	18,847
Cost, Disposals	(2,210)
Cost, Ending Balance	385,868	170,002
Accumulated Depreciation, Beginning Balance	104,918	42,802
Accumulated Depreciation, Depreciation	60,561	62,116
Accumulated Depreciation, Disposals	(902)
Accumulated Depreciation, Ending Balance	164,577	104,918
Net Book Value	221,291	65,084
Furniture and Fixtures [Member]
Cost, Beginning Balance	181,879	76,058
Cost, Additions	3,414	105,821
Cost, Disposals
Cost, Ending Balance	185,293	181,879
Accumulated Depreciation, Beginning Balance	29,585	11,845
Accumulated Depreciation, Depreciation	19,885	17,740
Accumulated Depreciation, Disposals
Accumulated Depreciation, Ending Balance	49,470	29,585
Net Book Value	135,823	152,294
Laboratory Equipment [Member]
Cost, Beginning Balance	352,637	245,729
Cost, Additions	3,350	246,375
Cost, Disposals		(139,467)
Cost, Ending Balance	355,987	352,637
Accumulated Depreciation, Beginning Balance	99,696	74,875
Accumulated Depreciation, Depreciation	51,151	86,368
Accumulated Depreciation, Disposals		(61,547)
Accumulated Depreciation, Ending Balance	150,847	99,696
Net Book Value	205,140	252,941
Leasehold Improvements [Member]
Cost, Beginning Balance	282,975	36,957
Cost, Additions	65,673	256,954
Cost, Disposals		(10,936)
Cost, Ending Balance	348,648	282,975
Accumulated Depreciation, Beginning Balance	36,206	9,220
Accumulated Depreciation, Depreciation	69,478	37,460
Accumulated Depreciation, Disposals		(10,474)
Accumulated Depreciation, Ending Balance	105,684	36,206
Net Book Value	$ 242,964	$ 246,769

Note 7 - Intangible Assets - Fi

Note 7 - Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Cost, Beginning Balance			$ 21,379	$ 21,379	$ 21,379
Cost, Additions			501,487
Cost, Ending Balance	$ 522,866		522,866		21,379
Accumulated Amortization, Beginning Balance			8,321	6,238	6,238
Accumulated Amortization, Amortization	273	$ 431	810	1,810	2,083
Accumulated Amortization, Ending Balance	9,131		9,131		8,321
Net Book Value	513,735		513,735		13,058
Computer Software, Intangible Asset [Member]
Cost, Beginning Balance			5,143	5,143	5,143
Cost, Additions			501,487
Cost, Ending Balance	506,630		506,630		5,143
Accumulated Amortization, Beginning Balance			5,143	4,143	4,143
Accumulated Amortization, Amortization					1,000
Accumulated Amortization, Ending Balance	5,143		5,143		5,143
Net Book Value	501,487		501,487
Trademarks [Member]
Cost, Beginning Balance			16,236	16,236	16,236
Cost, Additions
Cost, Ending Balance	16,236		16,236		16,236
Accumulated Amortization, Beginning Balance			3,178	$ 2,095	2,095
Accumulated Amortization, Amortization			810		1,083
Accumulated Amortization, Ending Balance	3,988		3,988		3,178
Net Book Value	$ 12,248		$ 12,248		$ 13,058

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	Jan. 01, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Number of Lease Agreements		2		2
Operating Lease, Right-of-Use Asset, Amortization		$ 127,345		$ 382,035		$ 0
Accounting Standards Update 2016-02 [Member]
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 1,613,038

Note 9 - Loan Arrangements (Det

Note 9 - Loan Arrangements (Details Textual) - Loan Arrangement With Shareholder [Member] - USD ($)	Oct. 17, 2017	Sep. 30, 2019
Debt Agreement, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term	5 years
Debt Agreement, Minimum Borrowing Per Advances	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Long-term Debt, Total		$ 0

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	Jun. 07, 2019	May 09, 2019	Jan. 14, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 16, 2019	Aug. 19, 2019	Jan. 10, 2019	Dec. 31, 2018
Preferred Stock, Shares Authorized				20		20					20
Share Price								$ 0.42	$ 0.26	$ 1.23
Proceeds from Issuance of Preferred Stock and Preference Stock						$ 12,000,000
Payments of Stock Issuance Costs				$ 1,414	$ 12,328	$ 627,681	$ 36,135
Private Placement [Member]
Payments of Stock Issuance Costs			$ 465
Series 1 Preferred Shares [Member]
Preferred Stock, Shares Authorized				20		20
Preferred Stock, Stated Value Per Share				$ 1,000,000		$ 1,000,000
Series 1 Preferred Shares [Member] | Private Placement [Member]
Preferred Stock, Value, Subscriptions		$ 12,000,000
Share Price		$ 1,000,000
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 7,000,000	$ 5,000,000
Payments of Stock Issuance Costs				$ 1,414		$ 38,603

Note 10 - Preferred Stock - Iss

Note 10 - Preferred Stock - Issued and Outstanding Preferred Stock (Details)	9 Months Ended
	Sep. 30, 2019USD ($)shares
Balance, number (in shares) | shares
Balance, amount | $
Balance, number (in shares) | shares	12
Balance, amount | $	$ 11,961,397
Series 1 Preferred Shares [Member]
Balance, number (in shares) | shares
Balance, amount | $
Stock issued from financing, number (in shares) | shares	12	[1]
Stock issued from financing, amount | $	$ 11,961,397	[1]
Balance, number (in shares) | shares	12
Balance, amount | $	$ 11,961,397
[1]	On May 9, 2019, the Company entered into subscription agreements to sell $12,000,000 of its Series 1 Preferred Shares to an accredited investor in a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share; $5,000,000 of the purchase price was paid on May 9, 2019 and the remaining $7,000,000 was paid on June 7, 2019. The Company recorded $1,414 and $38,603 of share issuance costs as an offset to preferred stock in the three and nine months ended September 30, 2019

Note 11 - Common Stock (Details

Note 11 - Common Stock (Details Textual) - USD ($)	Mar. 28, 2019	Jan. 14, 2019	Dec. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Gain (Loss) on Settlement of Liabilities						$ 19,737
Research and Development Expense, Total				962,463	630,371	9,555,345	3,765,332
Payments of Stock Issuance Costs				1,414	12,328	627,681	36,135
Proceeds from Issuance of Common Stock						3,000,000	$ 4,002,496
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		2,815,789
Proceeds from Issuance of Private Placement			$ 4,280,000
Payments of Stock Issuance Costs		$ 465
Public Offering [Member]
Stock Issued During Period, Shares, New Issues	6,521,740
Payments of Stock Issuance Costs				$ 0		$ 588,613
Proceeds from Issuance of Common Stock	$ 3,000,000
One Creditor [Member]
Debt Conversion, Converted Instrument, Amount		$ 75,000
Common Stock, Number of Shares, Issued		49,342
Common Stock, Value, Issued		$ 55,263
Gain (Loss) on Settlement of Liabilities		$ 19,737
Celsee [Member]
Common Stock, Number of Shares, Issued		657,894
Common Stock, Value, Issued		$ 1,000,000
Research and Development Expense, Total		$ 736,841

Note 11 - Common Stock - Issued

Note 11 - Common Stock - Issued and Outstanding Common Shares (Details) - USD ($)	Mar. 29, 2019	Mar. 15, 2019	Mar. 08, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019		Sep. 30, 2018
Number of common shares (in shares)						97,598,898
Stock issuance for services						$ 792,104		$ 1,238,513
Stock issuance for financing, net of costs						$ 14,372,319		$ 3,966,362
Stock issuance due to exercise of options (in shares)	65,789	164,473	164,473	0	85,000	394,735		1,866,996
Stock issuance due to exercise of options					$ 34,608	$ 600,000		$ 1,537,024
Number of common shares (in shares)				108,038,398		108,038,398
Common Stock [Member]
Number of common shares (in shares)						97,598,898		90,225,869
Capital stock						$ 30,410,648		$ 18,244,659
Stock issuance for services (in shares)						707,236	[1],[2]	641,717
Stock issuance for services						$ 792,104	[1],[2]	$ 1,238,513
Stock issuance for financing, net of costs (in shares)						9,337,529	[3],[4]	1,861,627
Stock issuance for financing, net of costs						$ 6,690,922	[3],[4]	$ 3,966,362
Stock issuance due to exercise of options (in shares)						394,735		1,866,996
Stock issuance due to exercise of options						$ 754,148		$ 1,923,922
Stock issuance for financing, net of costs (in shares)						9,337,529	[3],[4]	1,861,627
Number of common shares (in shares)				108,038,398	94,596,209	108,038,398		94,596,209
Capital stock				$ 38,647,822	$ 25,373,456	$ 38,647,822		$ 25,373,456
[1]	On January 14, 2019, the Company issued 657,894 common shares in satisfaction of $1,000,000 of all remaining milestones under a License and Supply Agreement with a third party. The Company recognized $736,841 as research and development expense, based on the value of the common stock on the date of issuance;
[2]	On January 14, 2019, the Company settled $75,000 of amounts due to a vendor by issuing 49,342 common shares valued at $55,263 at the date of issuance. The Company recorded a $19,737 gain on the settlement of liabilities during the three months ended March 31, 2019;
[3]	On January 14, 2019, the Company completed a non-brokered private placement, and issued 2,815,789 common shares. Gross proceeds of $4,280,000 were received prior to December 31, 2018. The Company recorded $465 of share issuance costs as an offset to common stock;
[4]	On March 28, 2019, the Company completed an underwritten public offering of its common stock pursuant to which the Company sold an aggregate 6,521,740 common shares for gross proceeds of $3,000,000. The Company recorded nil and $588,613 of share issuance costs as an offset to common stock in the three and nine months ended September 30, 2019.

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) $ / shares in Units, xbrli-pure in Thousands	Mar. 29, 2019shares	Mar. 15, 2019shares	Mar. 08, 2019shares	Jan. 10, 2019shares	Sep. 30, 2019USD ($)$ / sharesshares		Sep. 30, 2018USD ($)shares	Sep. 30, 2019USD ($)$ / sharesshares		Sep. 30, 2018USD ($)shares	Dec. 31, 2018$ / shares	Dec. 31, 2018$ / shares	[1]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares	65,789	164,473	164,473		0		85,000	394,735		1,866,996
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares				5,995,000	1,500,000		0	7,495,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | (per share)					$ 1.28	[1]		$ 1.28	[1]		$ 2.65	$ 1.95
Share-based Payment Arrangement, Expense					$ 197,988		$ 0	$ 2,539,092		$ 7,288
Proceeds from Stock Options Exercised					$ 0		98,716	600,000		1,537,024
Stock Issued During Period, Value, Stock Options Exercised							$ 34,608	$ 600,000		$ 1,537,024
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate					0.00%		0.00%	0.00%		0.00%
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Stock Options Exercised								$ (154,148)		$ (386,898)
[1]	As of the year ended December 31, 2018, the weighted average exercised price in CDN$ was $2.65.

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Issuance of Stock Options (Details)		Sep. 16, 2019$ / sharesshares	Aug. 19, 2019$ / sharesshares	Aug. 14, 2019$ / sharesshares	Aug. 13, 2019$ / sharesshares	Jun. 16, 2019$ / sharesshares	May 23, 2019$ / sharesshares	Mar. 29, 2019$ / sharesshares	Mar. 15, 2019$ / sharesshares	Mar. 08, 2019$ / sharesshares	Feb. 24, 2019$ / sharesshares	Jan. 10, 2019$ / sharesshares	Sep. 30, 2019$ / sharesshares		Sep. 30, 2018shares	Sep. 30, 2019$ / sharesshares		Sep. 30, 2018shares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2018$ / sharesshares
Number of Options, Options Outstanding (in shares)													7,040,265			7,040,265			422,004	422,004
Weighted Avg Exercise Price, Options Outstanding (in dollars per share) | (per share)													$ 1.28	[1]		$ 1.28	[1]		$ 2.65	$ 1.95	[1]
Number of Options, Options Granted (in shares)												5,995,000	1,500,000		0	7,495,000
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]											$ 1.52
Number of Options, Options Expired (in shares)				(392,004)		(40,000)	(10,000)				(35,000)
Weighted Avg Exercise Price, Options Expired (in dollars per share) | $ / shares	[1]			$ 2.07		$ 1.52	$ 1.52				$ 1.12
Number of Options, Options Exercised (in shares)								(65,789)	(164,473)	(164,473)			0		(85,000)	(394,735)		(1,866,996)
Weighted Avg Exercise Price, Options Exercised (in dollars per share) | $ / shares	[1]							$ 1.52	$ 1.52	$ 1.52
Number of Options, Options Cancelled (in shares)					(5,000)
Weighted Avg Exercise Price, Options Cancelled (in dollars per share) | $ / shares	[1]				$ 1.52
Options 1 [Member]
Number of Options, Options Granted (in shares)			500,000
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]		$ 0.26
Options 2 [Member]
Number of Options, Options Granted (in shares)			100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]		$ 0.35
Options 3 [Member]
Number of Options, Options Granted (in shares)			100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]		$ 0.45
Options 4 [Member]
Number of Options, Options Granted (in shares)			100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]		$ 0.55
Option 5 [Member]
Number of Options, Options Granted (in shares)			100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]		$ 0.65
Option 6 [Member]
Number of Options, Options Granted (in shares)			100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]		$ 0.75
Option 7 [member]
Number of Options, Options Granted (in shares)		500,000
Weighted Avg Exercise Price, Options Granted (in dollars per share) | $ / shares	[1]	$ 0.43
[1]	As of the year ended December 31, 2018, the weighted average exercised price in CDN$ was $2.65.

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Details of the Issued Stock Options (Details) - $ / shares		Aug. 19, 2019	Jan. 10, 2019	Sep. 30, 2019	Dec. 31, 2018
Weighted Avg Exercise Price, Options Granted (in dollars per share)	[1]		$ 1.52
Number of Options, Options Outstanding (in shares)				7,040,265	422,004
Number of Vested Options (in shares)				7,040,265
Options 1 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	[1]	$ 0.26
Options 2 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	[1]	0.35
Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	[1]	0.45
Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	[1]	0.55
Option 5 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	[1]	0.65
Option 6 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	[1]	$ 0.75
January 10, 2019 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)				$ 1.52
Number of Options, Options Outstanding (in shares)				5,540,265
Number of Vested Options (in shares)				5,540,265
Weighted Avg Remaining Life (Year)				1 year 102 days
August 16, 2019 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)				$ 0.26
Number of Options, Options Outstanding (in shares)				500,000
Number of Vested Options (in shares)				500,000
Weighted Avg Remaining Life (Year)				1 year 321 days
August 16, 2019 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)				$ 0.35
Number of Options, Options Outstanding (in shares)				100,000
Number of Vested Options (in shares)				100,000
Weighted Avg Remaining Life (Year)				1 year 321 days
August 16, 2019 [Member] | Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)				$ 0.45
Number of Options, Options Outstanding (in shares)				100,000
Number of Vested Options (in shares)				100,000
Weighted Avg Remaining Life (Year)				1 year 321 days
August 16, 2019 [Member] | Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)				$ 0.55
Number of Options, Options Outstanding (in shares)				100,000
Number of Vested Options (in shares)				100,000
Weighted Avg Remaining Life (Year)				1 year 321 days
August 16, 2019 [Member] | Option 5 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)				$ 0.65
Number of Options, Options Outstanding (in shares)				100,000
Number of Vested Options (in shares)				100,000
Weighted Avg Remaining Life (Year)				1 year 321 days
August 16, 2019 [Member] | Option 6 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)				$ 0.75
Number of Options, Options Outstanding (in shares)				100,000
Number of Vested Options (in shares)				100,000
Weighted Avg Remaining Life (Year)				1 year 321 days
September 16, 2019 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)				$ 0.43
Number of Options, Options Outstanding (in shares)				500,000
Number of Vested Options (in shares)				500,000
Weighted Avg Remaining Life (Year)				1 year 350 days
[1]	As of the year ended December 31, 2018, the weighted average exercised price in CDN$ was $2.65.

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Valuation Assumptions for Fair Value of Options Granted (Details) - $ / shares	Sep. 16, 2019	Aug. 19, 2019	Jan. 10, 2019
Volatility	89.00%	87.00%	68.00%
Risk-free interest rate	1.74%	1.48%	2.56%
Expected life (years) (Year)	2 years	2 years	2 years
Dividend yield	0.00%	0.00%	0.00%
Common share price (in dollars per share)	$ 0.42	$ 0.26	$ 1.23
Strike price (in dollars per share)	$ 0.43		$ 1.52
Minimum [Member]
Strike price (in dollars per share)		0.26
Maximum [Member]
Strike price (in dollars per share)		$ 0.75

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Details Textual) - USD ($)	Nov. 26, 2018	May 10, 2018
Qorvo Biotechnologies, LLC [Member]
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Cash Only	$ 3,000,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Cash Portion	1,500,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Equity Portion	1,950,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Fourth Payment, Cash Only	$ 2,000,000
Seraph Biosciences, Inc. [Member]
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Cash		$ 3,500,000
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Equity		$ 3,500,000

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies - Future Annual Lease Payments (Details)	Sep. 30, 2019USD ($)
2019	$ 12,480
2020	33,280
Total	$ 45,760

Note 14 - Financial Instrumen_3

Note 14 - Financial Instruments - Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accounts Payable and Accrued Liabilities, Maturity Less Than 3 Months	$ 1,577,525	$ 2,376,519
Accounts payable and accrued liabilities, Maturity 3 to 6 Months
Accounts payable and accrued liabilities, Maturity 6 to 9 Months
Accounts payable and accrued liabilities, Maturity 9 to 12 Months
Accounts payable and accrued liabilities, Maturity Greater Than 1 Year
Accounts payable and accrued liabilities	1,577,525	2,376,519
Contractual Financial Liabilities, Maturity Less Than 3 Months	1,577,525	2,376,519
Contractual Financial Liabilities, , Maturity 3 to 6 Months
Contractual Financial Liabilities, Maturity 6 to 9 Months
Contractual Financial Liabilities, Maturity 9 to 12 Months
Contractual Financial Liabilities, Maturity Greater Than 1 Year
Contractual Financial Liabilities	$ 1,577,525	$ 2,376,519

Note 15 - Segmented Informati_3

Note 15 - Segmented Information - Long-lived Assets by Geographic Areas (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Assets	$ 6,611,024		$ 6,033,519
Total US property and equipment	805,218		717,088
Total US right-of-use asset	1,231,003	$ 1,613,038
CANADA
Assets	431,063		383,567
UNITED STATES
Assets	6,179,961		5,649,952
Total US property and equipment	805,218		717,088
Total US right-of-use asset	1,231,003
	$ 2,036,221		$ 717,088

Note 16 - Schedule of Expense_2

Note 16 - Schedule of Expenses - Schedule of Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and development	$ 962,463	$ 630,371	$ 9,555,345	$ 3,765,332
Professional fees	279,237	293,484	1,230,151	1,001,886
General and administrative	1,404,952	834,570	5,557,661	3,243,232
Salaries, Bonus and Benefits [Member]
Research and development	129,319	164,267	579,110	490,706
Professional fees
General and administrative	849,458	454,786	4,422,480	1,957,341
Contracted Expenditures [Member]
Research and development	661,917	259,947	2,474,483	968,159
Professional fees
General and administrative
Marketing and Investor Relations [Member]
Research and development
Professional fees
General and administrative	165,837	53,996	297,252	177,151
Travel and Accommodation [Member]
Research and development	8,327	8,023	21,103	13,360
Professional fees
General and administrative	198,993	36,491	318,730	228,359
Insurance [Member]
Research and development	19,497	20,855	76,402	65,099
Professional fees
General and administrative	66,029	76,903	179,367	234,646
License Fees [Member]
Research and development			5,936,841	1,738,513
Professional fees
General and administrative
Office [Member]
Research and development	11,565	6,665	31,162	41,312
Professional fees
General and administrative	80,032	82,416	216,521	220,823
Consultant [Member]
Research and development	29,343	80,425	178,223	169,613
Professional fees	279,237	293,484	1,230,151	1,001,886
General and administrative
Regulatory [Member]
Research and development	31,773	19,247	95,418	57,422
Professional fees
General and administrative	26,163	32,904	76,333	226,604
Amortization, Right-of-use Asset [Member]
Research and development		15,396		31,047
Professional fees
General and administrative	7,603	90,463	19,483	176,501
Supplies [Member]
Research and development	70,722	55,546	162,603	190,101
Professional fees
General and administrative	$ 10,837	$ 6,611	$ 27,495	$ 21,807

Note 18 - Loss Per Share - Loss

Note 18 - Loss Per Share - Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss for the period	$ 2,845,679	$ 1,910,278	$ 16,927,016	$ 8,226,005
Weighted average shares - basic (in shares)	108,038,398	94,514,905	105,711,459	92,534,667
Stock options (in shares)
Denominator for diluted loss per share (in shares)	108,038,398	94,514,905	105,711,459	92,534,667
Loss per share - basic and diluted (in dollars per share)	$ (0.03)	$ (0.02)	$ (0.16)	$ (0.09)

Note 19 - Related Party Trans_3

Note 19 - Related Party Transactions and Key Management Compensation - Key Management Personnel Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock-based compensation	$ 197,988	$ 0	$ 2,539,092	$ 7,288
Director and Executive Officers [Member]
Salaries and benefits, including bonuses	251,737	324,784	887,635	1,046,449
Stock-based compensation	100,002		1,744,327
Total	$ 351,739	$ 324,784	$ 2,631,962	$ 1,046,449